EUCAST SOPs are reviewed at regular intervals. When the SOP has been assigned a new date and a new version number, information has been added or removed. When the version number is unchanged, but a new date has been added, the review did not result in any change. During May 2025 all SOPs are reviewed.
07 May 2025: Proposed revision of breakpoints for trimethoprim-sulfamethoxazole and trimethoprim.
The current breakpoints of trimethoprim-sulfamethoxazole are higher than the epidemiological cut-off values for several species. There is absence of PK/PD data for systemic infections, and there is also absence of clinical data linking MIC to outcomes. Thus, the historical clinical breakpoints for Enterobacterales are not well substantiated, and the logical way forward would be to base new breakpoints on ECOFFs, as was recently done for Stenotrophomonas maltophilia.
